Surgeries & Interventions

Physiological Pacing Movement Gains Momentum

Conduction System pacing-2 (2)

Physiological pacing has witnessed tremendous growth in the last ten years, and new funding may provide the evidence physicians need to make it the heart failure standard of care. 

PCORI awarded $31M to Baylor University researchers to compare the standard Biventricular pacing (BiV) with the emerging conduction system pacing (CSP) – two cardiac resynchronization therapies that restore healthy heartbeat patterns in both HF and reduced ejection fraction patients.  

BiV improves heart failure in 60-70% of patients by pacing simultaneously from two discrete sites: the right ventricular apex and the left lateral wall. In contrast, CSP relies on one lead implanted at either the His bundle or left bundle branch to directly stimulate the heart’s native conduction network. It is considered more physiologic, and it closely reproduces what happens naturally. 

Observational and small-scale RCTs have shown that CSP produces equal or even better QRS duration and LV function improvements and possibly greater hemodynamic benefits. But CSP still needs to pass a large-scale RCT test before widespread adoption can happen. 

Enter: PCORI-funded Baylor researchers. Here is what we know about how they plan to investigate the long-term mortality benefits and safety of CSP compared to BiV: 

  • Fifty-five centers will randomly assign more than 2k eligible patients to receive either CSP or BiV pacing. 
  • Follow-up will be five years. 
  • The endpoints will be death and heart failure hospitalization. 

The Takeaway

This multi-center trial will answer an important clinical question on pacing and heart failure, and may very well impact clinical practice in EP and HF. 

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiac Imaging June 16, 2025

Beyond Hardware: Is AI the Answer to Making Cardiac Imaging more Accessible? June 16, 2025

Sponsored by Philips Healthcare Cardiac imaging has traditionally improved through hardware advances, enabling the speed needed for high-quality images. However, hardware is rapidly reaching its physical limitations in suppressing cardiac motion and represents a large financial investment. Today, software and AI are driving the next leap in cardiac image quality and motion control – offering […]

Cardiology Pharmaceuticals June 12, 2025

FDA Approves a New BP Triple Polypill June 12, 2025

Bringing a more effective BP therapy to the U.S. market, the FDA approved George Medicines’ triple therapy polypill called Widaplik for patients with hypertension, making it the first of its kind to go to market in the U.S. Widaplik’s approval stems from two studies, including one comparing the polypill against placebo as an initial treatment […]

Cardiology Pharmaceuticals June 12, 2025

Pharmacologic Preconditioning to Improve Outcomes in Patients Undergoing Cardiac Surgery  June 12, 2025

The majority of patients undergoing cardiac surgery, especially those on cardiopulmonary bypass (CPB), experience post-operative complications such as new-onset atrial fibrillation (POAF) and acute kidney injury (AKI), largely driven by oxidative stress and inflammation.   Several approaches have been explored to reduce complications following cardiac surgery, however, a clinically meaningful impact has yet to be realized.  […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!